CuraGen Announces Initiation Of Phase II Trial Of CR011-vcMMAE In Patients With Advan
 

CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced today the treatment of the first patient in its CR011-vcMMAE Phase II breast cancer study. The Phase II trial is an open-label, multi-center study of CR011-vcMMAE administered intravenously once every three weeks to patients with locally-advanced or metastatic breast cancer who have received prior therapy.

More...

This is exciting - sounds like a similar molecule to Herceptin-DM1 (an antibody linked to a "toxin") but targeting a different protein. Another smart bomb for the arsenal.

chrisy... u r correct... another smart bomb technology by curagen using a toxin from seattle genetics.

eventually both companies drugs from genentech and curagen will both be approved